Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists.
Loading...
Issue Date
2021-10
Authors
Patel, Nimish
Bouchard, Jeannette
Oliver, Meredith B
Badowski, Melissa E
Carreno, Joseph J
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
As of August 2021, there were three COVID-19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID-19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA-1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real-world effectiveness investigations post-authorization. These studies indicate that immunity is obtained within 2 weeks post-vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS-CoV-2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID-19 vaccine programs.
Citation
Patel N, Bouchard J, Oliver MB, Badowski ME, Carreno JJ; Society of Infectious Diseases Pharmacists. Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2021 Oct;41(10):837-850. doi: 10.1002/phar.2622. PMID: 34689348.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).